Novasep CDMO

KYCO: Know Your Company

Reveal Profile

28 October 2025

1) Overview of the Service Provider

Novasep CDMO is a leading Contract Development and Manufacturing Organization specializing in complex small molecule APIs, biopharmaceuticals, and antibody-drug conjugates (ADCs). The company operates as part of Axplora Group, formed following the 2022 merger of Novasep with PharmaZell and Farmabios. With over thirty years of experience, Novasep CDMO has established itself as a key partner for pharmaceutical and biotech innovators worldwide, supporting the development and manufacturing of best-in-class APIs that improve the quality of life for millions of patients globally.

The service provider offers comprehensive contract development and manufacturing solutions for small molecule APIs and biopharmaceuticals across the entire drug lifecycle, from early-stage development to commercial production. Novasep CDMO’s industrial footprint encompasses an extensive network of flexible cGMP manufacturing assets across multiple sites in full regulatory compliance, providing customers with a secured supply chain. The company operates 10 API manufacturing sites in Europe and India, maintaining a 100% successful inspection rate by US-FDA and European authorities.

Novasep CDMO’s competitive positioning is strengthened by its portfolio of 15 differentiating technologies and over 140 agile process development experts. The company has achieved significant milestones including 15 client drugs approved by the FDA in the last 6 years and has invested over 90 million euros in site improvements over the last 5 years. The organization conducts approximately 40 audits per year, demonstrating its commitment to regulatory compliance and quality standards.

The company’s technology platform includes world-leading capabilities in industrial chromatography, hazardous and cryogenic chemistry, electrochemistry, flow chemistry, solid state chemistry, and lipid production. Novasep CDMO specializes in high-potency APIs (HPAPIs), cytotoxic compounds, and advanced ADC manufacturing services, including payload-linker development and bioconjugation. The company’s expertise spans natural extracts and biomolecules purification, positioning it as a comprehensive solution provider for complex pharmaceutical manufacturing challenges.

Novasep CDMO serves pharmaceutical innovators, cosmetic ingredients manufacturers, and agrochemical companies through its global R&D capabilities with laboratories and pilot plants across the US, Europe, and Asia. The company’s decade-long relationships with key customers and proven track record in developing and manufacturing APIs using advanced technologies such as continuous chromatography and specialized purification processes have established its reputation as a preferred CDMO partner in the industry.

2) History

Novasep CDMO’s history spans over thirty years, beginning as a preparative chromatography company founded circa 1995 by Roger-Marc Nicoud. The company emerged as a start-up producing pharmaceuticals, biopharmaceuticals, and purification technologies for food markets, establishing its foundation in Lyon, France. During its early years, Novasep grew significantly through strategic acquisitions, including the 1999 acquisition of Prochrom, which added API manufacturing to the firm’s services and gave it a leading position in simulated moving-bed purification.

The company expanded its API business in 2003 with the purchase of Seripharm, which manufactured the cancer drug paclitaxel. In 2004, the US firm Rockwood Holdings engineered the merger of Novasep with Rockwood’s Dynamic Synthesis unit, creating a large European player in pharmaceutical services. Within two years, Novasep management along with several investment partners bought the combined company from Rockwood.

Heavy spending caught up with Novasep in the economic downturn of 2009 when a 10% increase in interest on the bonds it had issued to support its expansion pushed debt to about $500 million. Novasep teetered financially until 2011, when ownership passed to bondholders, including the US investment funds Tennenbaum Capital Partners, Silver Point Capital, and Pimco. The new owners’ refinancing effort saved the company, bringing debt below $200 million within a year.

From 2011 onwards, the focus shifted to organic growth under new management, with Michel Spagnol joining as CEO in 2013 after leading another CDMO, Rhodia ChiRex. The company continued to invest in growing businesses such as omega-3 fatty acid APIs at a facility in Mourenx, France, becoming a major producer when it signed a contract to supply Amarin with the omega-3 in the cardiac therapy Vascepa. Novasep also invested significantly in antibody-drug conjugates, adding bioconjugation services to its small-molecule ADC payload business in Le Mans, France.

In 2021, Novasep’s Belgium viral vector manufacturing division, Henogen, was sold to Thermo Fisher for €725 million, completing the process of remaking Novasep into a contract development and manufacturing organization emphasizing small-molecule active pharmaceutical ingredient production and tightly focused on customer molecules in late-stage clinical trials or on the market.

The transformative milestone in Novasep CDMO’s history occurred in April 2022 when the company completed its merger with PharmaZell, following exclusive negotiations initiated in September 2021. This strategic merger created Axplora Group, a technology-driven, leading CDMO and API manufacturer with nearly €500 million in revenues and over 2,000 employees across ten production and R&D sites in Europe, the United States, and India. The transaction was backed by PharmaZell’s majority shareholder Bridgepoint Group, with former Novasep CEO Michel Spagnol joining the Board of Directors.

3) Key Executives

Martin Meeson joined Axplora as Chief Executive Officer on April 9, 2024, bringing over two decades of experience in managing and growing businesses globally. Martin succeeded Sylke Hassel in the CEO role and brings deep passion for the pharmaceutical sector, the customers they serve, and the partnerships they create. In his previous role as CEO at Fujifilm Diosynth Biotechnologies, he successfully steered the business through the pandemic, supporting the development of numerous treatments and vaccines. He built his business foundation in manufacturing of fine chemicals and qualified as a chartered accountant with KPMG.

Dr. Edgar Lange serves as Chief Financial Officer, having joined the company in 2000. Edgar brings over 25 years of experience as a CFO for different companies including Rodenstock Group, Müller Group, and Lekkerland wholesale. He started his career as Consultant at McKinsey & Company in Munich and Buenos Aires in 1992, and throughout his career has held several Board seats, including stock listed companies. Edgar holds a Master’s degree in industrial engineering from the Technical University of Karlsruhe and a PhD degree in Economics.

Dr. Pere Paton Morales joined Axplora as Chief Operating Officer on March 1, 2023. As a chemist, he started his professional life in the fine chemical sector in Spain, dealing with innovative and complex projects. Prior to his most recent role as Chief Quality & Technical Operations Officer at Centrient, Pere worked with Boehringer Ingelheim and Apotex, where he was President for Global API and Executive Vice President for Global API & Procurement. He holds a Master’s degree in Industrial Chemistry and a PhD degree in Chemical Engineering from the University of Barcelona, plus an MBA from ESADE Business School in Spain.

Arul Ramadurai joined Axplora as Chief Commercial Officer on July 18, 2022. Based in Raubling Germany, Arul oversees the Global Marketing Strategy and Business Intelligence and has a global role bringing together the BU Marketing organizations. A Chartered Chemical Engineer from the UK with an MBA from INSEAD, Arul has a 25-year business career as a General Manager, Executive Coach and Commercial Negotiator. He led Commercial Marketing & Sales and Operational Technical Operations & Supply Chain organizations at Novartis, Baxalta & Shire and has also served as CEO of a Swiss Biologics CDMO.

Dr. Stephan Haitz was appointed President of the Novasep CDMO Business Unit in November 2023, taking over from Jean Bléhaut who departed after over 25 years with the company. Stephan has over 20 years of business career experience in the pharmaceutical industry, holding various management positions within global CDMOs such as Solvias, Lonza and Cambrex. Most recently, he worked as President Drug Substance CDMO Commercial at Cambrex. He holds a PhD and Master in organic chemistry and a Bachelor of Science in economics.

Mario Di Giacomo serves as President of the Steroids & Highly Potent Products Business Unit and Managing Director of Axplora’s site in Italy. He has been with Axplora since 2014 and has over 20 years of industry experience in APIs. Before joining, he held various positions at Fabbrica Italiana Sintetici S.p.A for eight years and worked as a plant operations manager at Erregierre S.p.A for six years. Mario holds a Master’s degree in Industrial Chemical Engineering from the University of Bologna with a specialty in Economics.

Anant Barbadikar is the Managing Director and Chief Operating Officer in India as well as Co-President of the Specialty Products BU at Axplora. He joined the Group in 2007 as Managing Director and is based in Andhra Pradesh, India. Previously, Anant was Senior Director at Dr. Reddy’s Laboratories for five years and started his career at Gharda Chemicals in 1990. He is a chemical engineer from Laxminarayan Institute of Technology India and TQM certified from OSAKA university, Japan.

Stephan Bregy joined Axplora in 2017 and serves as President of the Specialty Products BU. He started in the company as Head of Marketing & Sales for five years before taking over his current position in 2022. He began his career in 1997 at Lonza as an International Product Manager and also worked at DePuy Synthes and at Siegfried for eight years. He has over 25 years of experience in the pharmaceutical and life science industry and received a Bachelor in Business from HEC Lausanne University.

4) Ownership

Novasep CDMO operates as a wholly-owned subsidiary within the Axplora Group structure, which was formed through the strategic merger of Novasep with PharmaZell and Farmabios in April 2022. The transaction was backed by PharmaZell’s majority shareholder Bridgepoint Group, with the combined entity generating nearly €500 million in revenues and employing over 2,000 employees across ten production and R&D sites globally.

Bridgepoint Group PLC serves as the majority shareholder of Axplora, described as the world’s leading quoted private assets growth investor focused on the middle-market with €32 billion assets under management and a local presence in the US, Europe and China. The private equity firm specializes in private equity and private credit, investing internationally in six principal sectors including medtech and pharma. Bridgepoint initially invested in PharmaZell Group in 2020 before backing the subsequent merger with Novasep in 2022.

The ownership structure operates through European holding companies, with European Medco Development 3 S.a.r.l. serving as the primary issuer entity that indirectly owns Axplora. The capital structure includes senior secured debt instruments, with European Medco Development 4 S.a.r.l. issuing senior secured debt rated ‘B’ by Fitch Ratings. The debt structure comprises a €520 million term loan B and a €92.5 million revolving credit facility ranking equally among themselves.

Financial backing for Novasep CDMO within the Axplora structure has been strengthened through various capital investments and strategic initiatives. The group has invested over €90 million in site improvements over the last five years, demonstrating continued capital commitment to operational excellence. Recent major investments include €8 million in the Le Mans facility for ADC manufacturing expansion and €50 million in the Mourenx site for GLP-1 manufacturing capabilities, with the latter investment being customer-funded.

Prior to the 2022 merger, Novasep had undergone significant ownership changes, including a 2011 debt restructuring that brought ownership to bondholders including US investment funds Tennenbaum Capital Partners, Silver Point Capital, and Pimco. The company’s viral vector manufacturing division Henogen was divested to Thermo Fisher Scientific for €725 million in January 2021, completing the process of refocusing Novasep as a contract development and manufacturing organization emphasizing small-molecule API production.

5) Legal Claims and Actions

Based on available regulatory and legal databases, no material legal claims, regulatory actions, disciplinary measures, fines, sanctions, or criminal proceedings have been identified involving Novasep CDMO or its subsidiaries Novasep Holding, Inc. and Novasep Process SAS as of October 2025.

The absence of documented legal and regulatory actions in major databases including SEC enforcement records suggests that Novasep CDMO has maintained compliance with applicable regulatory frameworks governing contract development and manufacturing organizations. This clean regulatory record aligns with the company’s stated commitment to maintaining 100% successful inspection rates by US-FDA and European authorities across its manufacturing network.

Given Novasep CDMO’s role as a pharmaceutical contract manufacturer operating across multiple jurisdictions including the United States, Europe, and India, the company remains subject to extensive regulatory oversight by agencies such as the FDA, EMA, and other national health authorities. The company’s manufacturing operations are governed by current Good Manufacturing Practice (cGMP) regulations, which carry significant compliance obligations and potential enforcement actions for violations.

6) Recent Media Coverage

Between 2023 and 2025, media coverage concerning Novasep CDMO has largely focused on strategic investments by its parent company, Axplora, to enhance manufacturing capabilities, alongside shifts in executive leadership and mixed financial performance assessments for the business unit. In October 2025, Axplora announced that investments initiated across its global network in 2025 would exceed €100 million, including an increased allocation of €60 million for the Mourenx, France site. This followed an earlier announcement in February 2025 of a €50 million customer-funded project at the same facility to establish production for GLP-1 drug substances, with initial supplies anticipated in 2026.

Investment in antibody-drug conjugate (ADC) manufacturing capabilities, a core focus for the Novasep CDMO unit, has also been prominent. Axplora launched a new payload manufacturing workshop at its Le Mans, France facility in March 2025. This expansion builds on a previously announced €8 million investment in January 2024 to increase ADC payload capacity at the same site, which is part of the France 2030 government program. In a February 2023 interview, the company also noted the addition of drug product testing services to its ADC offerings to create a more integrated service.

On the regulatory front, the Novasep CDMO site in Chasse-sur-Rhône, France, successfully passed its ninth consecutive inspection by the French National Agency for Medicines and Health Products Safety (ANSM) in June 2025, confirming its full compliance with cGMP standards. This contributes to the parent group’s strong regulatory record, which also saw its sites in India pass USFDA inspections in 2025.

Credit rating agencies have provided varied outlooks on the business. In August 2023, Fitch Ratings downgraded Axplora’s parent entity, citing significant underperformance at the Novasep division following the loss of three key contracts. Fitch reaffirmed this view in a July 2024 report, identifying the lost contracts as being with Amarin, Pfizer, and AstraZeneca, and noting high execution risk in turning the unit around. However, in August 2024, S&P Global Ratings revised Axplora’s outlook to stable from negative, acknowledging improved profitability and that a new leadership team was addressing the earlier challenges. In June 2025, Fitch affirmed its rating but reiterated that Novasep’s performance was weaker than expected, though it anticipated a mild recovery.

The Novasep CDMO unit has seen notable leadership turnover. In October 2023, Axplora appointed Dr. Stephan Haitz as President, replacing a 25-year veteran of the company. Dr. Haitz’s tenure was brief, as he departed in June 2024 to join CordenPharma as Chief Commercial Officer. Additionally, former Novasep CEO Michel Spagnol was appointed Chairman of the board at Astraveus SAS in November 2023, though he retained his role on Axplora’s board. In April 2024, a Market Director with 16 years at Novasep and Axplora also announced his retirement. A review of media coverage did not identify any reports of major legal disputes, ESG controversies, cybersecurity incidents, or other significant crises affecting Novasep CDMO during the 2023-2025 period.

7) Strengths

Advanced Technology Portfolio

Novasep CDMO distinguishes itself through a portfolio of 15 differentiating technologies that provide significant competitive advantages in complex pharmaceutical manufacturing. The company has established world-leading capabilities in industrial chromatography, positioning it as a pioneer in continuous chromatography with the largest FDA-audited commercial-scale continuous chromatography platform globally. This technological foundation encompasses hazardous and cryogenic chemistry, electrochemistry, flow chemistry, solid state chemistry, and lipid production capabilities that enable the company to tackle complex synthesis challenges that competitors cannot address. The company’s expertise in high-potency APIs (HPAPIs) and cytotoxic compounds, combined with advanced ADC manufacturing services including payload-linker development and bioconjugation, positions it uniquely in the rapidly growing targeted therapy market.

Market Leadership in ADCs

Novasep CDMO has achieved a dominant position in the antibody-drug conjugate market, supplying 40% of the world’s marketed ADCs and 50% of FDA-approved ADCs. With over 20 years of experience in the ADC space and more than 250 cGMP ADC batches produced, the company has developed comprehensive capabilities spanning from payload development to bioconjugation at its Le Mans facility. The recent €8 million investment in Le Mans to expand ADC payload manufacturing capacity demonstrates the company’s commitment to maintaining its leadership position in this high-growth therapeutic area. This market dominance is supported by six dedicated ADC workshops that provide integrated solutions from clinical payload-linker production to commercial payloads and bioconjugation services.

Exceptional Regulatory Track Record

The company maintains a 100% successful inspection rate by US-FDA and European authorities across its manufacturing network, demonstrating exceptional quality management and regulatory compliance. Novasep CDMO’s regulatory excellence is exemplified by its Chasse-sur-Rhône site, which has successfully passed nine consecutive regulatory inspections, including the most recent ANSM inspection in February 2025 with no critical remarks or 483 observations. This outstanding track record extends across all manufacturing sites, with successful FDA inspections at Le Mans, Mourenx, and Leverkusen facilities, providing customers with confidence in supply security and regulatory compliance for commercial and clinical products.

Global Manufacturing Network and Scale

Novasep CDMO operates a comprehensive network of 10 API manufacturing sites across Europe and India, providing flexible cGMP manufacturing assets that ensure supply chain security and geographic diversification. The company’s global R&D capabilities span laboratories and pilot plants across the US, Europe, and Asia, enabling comprehensive support from early-stage development through commercial manufacturing. With over 140 agile process development experts and the capability to conduct approximately 40 audits per year, the company demonstrates the scale and expertise necessary to support large pharmaceutical and biotech customers across multiple development stages simultaneously.

Customer-Centric Partnership Approach

The company has established decade-long relationships with key customers, reflecting its ability to serve as a trusted strategic partner rather than a transactional supplier. Novasep CDMO’s track record includes 15 client drugs approved by the FDA in the last 6 years, demonstrating its capability to successfully support molecules through regulatory approval and commercial launch. The company’s customer-focused approach is evidenced by over €90 million invested in site improvements over the last 5 years, showing its commitment to continuously enhancing capabilities to meet evolving customer needs and maintain competitive manufacturing standards.

Proven Investment in Innovation

Novasep CDMO’s commitment to innovation is demonstrated through continuous investment in cutting-edge technologies and capacity expansion. Recent investments include €50 million in the Mourenx site for GLP-1 manufacturing capabilities and the establishment of cGMP flow chemistry capabilities at the Chasse-sur-Rhône site. The company’s innovation focus extends to next-generation manufacturing processes, including the implementation of continuous chromatography systems and specialized purification processes that provide customers with more efficient and cost-effective manufacturing solutions compared to traditional batch processes.

8) Potential Risk Areas for Further Diligence

Recent Leadership Instability

The Novasep CDMO business unit has experienced significant leadership turnover at the presidential level, creating potential continuity risks for strategic direction and client relationships. Dr. Stephan Haitz was appointed President in November 2023, replacing Jean Bléhaut who departed after over 25 years with the company. However, Haitz’s tenure was brief, as he left in June 2024 to join CordenPharma as Chief Commercial Officer, leaving the business unit without consistent leadership for multiple quarters. This pattern of senior leadership changes, combined with the departure of a 25-year veteran, may indicate underlying challenges in the business unit’s strategic direction or operational performance that warrant investigation.

Significant Business Unit Underperformance

Credit rating agencies have consistently highlighted material underperformance at the Novasep CDMO division following the loss of three key customer contracts with Amarin, Pfizer, and AstraZeneca. Fitch Ratings reported that this resulted in Novasep’s EBITDA contracting by two-thirds and revenue declining by 40% from FY23 levels, with the business unit’s contribution to group EBITDA decreasing sharply to 14% in FY25 from 42% in FY23. S&P Global Ratings noted in August 2023 that this “significant underperformance at the Novasep division” was severe enough to trigger a credit rating downgrade for the parent company. The business unit’s EBITDA margin contracted to 8.5% in FY25 from 12.2% in FY24 despite cost-cutting efforts, indicating persistent operational challenges that require detailed examination.

High Execution Risk in Recovery Strategy

Rating agencies have expressed skepticism about Novasep CDMO’s ability to successfully execute its turnaround strategy, with Fitch describing “high execution risk in turning it around” and noting that recovery efforts would be “challenging to replace the lost volumes in the near term.” The business unit is being repositioned under new management, but the track record of recent leadership instability raises questions about the sustainability of any recovery plan. Credit analysts project only a “mild recovery” at Novasep, suggesting limited confidence in the current strategic approach and execution capabilities.

Customer Concentration and Contract Vulnerability

The substantial impact from losing three key customer contracts demonstrates dangerous customer concentration within the Novasep CDMO portfolio, creating ongoing revenue volatility risk. The fact that contract losses with three clients could reduce EBITDA by two-thirds indicates insufficient diversification and potential over-reliance on large customer relationships. This concentration risk is particularly concerning in the CDMO industry where customer relationships can be disrupted by competitive pressures, internal customer changes, or quality issues. The business unit’s ability to replace these significant contracts remains uncertain, creating ongoing execution risk for revenue stability.

Integration and Operational Complexity

Operating within the complex Axplora Group structure, which was formed through multiple mergers including Novasep, PharmaZell, and Farmabios, creates potential integration risks and operational inefficiencies. The business unit must navigate shared services, coordinated quality systems, and integrated supply chains across multiple geographic locations while maintaining its distinct CDMO focus. The challenge of integrating different corporate cultures, quality systems, and operational procedures across the merged entities may continue to create execution risks and operational disruptions that could impact client service delivery and business performance.

Regulatory and Quality Management Scalability

While Novasep CDMO maintains an excellent regulatory track record with 100% successful inspection rates, the business unit’s operational challenges amid the broader Axplora integration raise questions about the scalability and sustainability of its quality management systems during periods of business stress. The need to maintain stringent cGMP compliance across multiple sites while managing business unit restructuring and leadership changes creates potential quality system risks that require continuous monitoring to ensure regulatory standards are maintained throughout any recovery period.

Save as PDF